Surgery vs. PCI in Diabetic Patients with Multivessel Disease

Original Title: Revascularization in diabetics with multivessel disease: a population-based evaluation of outcomes.
Presenter: Ramanathan K.

Real-world data support the role of CABG over PCI in diabetic patients with multivessel disease. However, PCI continues to be a common ­­­­­­option for this patient population, according to an analysis of 2 Canadian registries.

Sourcing data from 2 registries in British Columbia, researchers analyzed 4,819 patients: 2,888 PCI and 1,931 CABG procedures between October 2007 and January 2014 in patients with diabetes and multivessel disease.

The adjusted 30-day risks of most adverse events were lower with CABG, except for stroke risk, which was lower with PCI. However, all long-term endpoints through 5 years favored CABG over PCI.

When separating results by diagnosis, we can see greater benefit in terms of all-cause mortality, non-fatal infarction and stroke with CABG over PCI in patients with stabilized acute coronary syndrome (4.4% vs 8.3%; P < 0.01), vs. those with stable ischemic heart disease, at 30 days (1.5% vs 2.3%; P = .30; Pfor interaction< 0.01). The long term benefit of surgery over PCI (31 days-5 years) was similar for both diagnosis (P< .01 for both).

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...